Why did AELIS.PA stock spike today?

AELIS.PA stock rose after Aelis Farma confirmed active recruitment for its Phase 2b trial in France, Italy and Spain. Higher volume and positive sentiment around trial execution drove the **26.83%** intraday gain to **€1.56**.

What is Meyka AI's rating for AELIS.PA stock?

Meyka AI rates AELIS.PA **64.62/100**, Grade **B** with a **HOLD** suggestion. The score combines benchmark comparison, sector metrics, growth and analyst signals; it is informational and not investment advice.

What price target does Meyka AI give for AELIS.PA stock?

Meyka AI's forecast model projects a 12-month fair value of **€2.75**, implying an upside of **76.28%** from the current **€1.56**. Forecasts are model projections and not guarantees.

What are the main risks for AELIS.PA stock investors?

Primary risks include clinical trial setbacks, R&D cash burn leading to dilution, and high volatility due to small market cap and low liquidity. Financial metrics like EPS **-0.60** and debt/equity **1.13** also raise execution risk.

EU Stocks

AELIS.PA stock +26.83% to €1.56 (23 Mar 2026): recruitment lifts Phase 2 outlook

ByDanny Kontos March 24, 2026March 24, 2026

AELIS.PA stock led today’s top gainers on EURONEXT, rising 26.83% to €1.56 as the company confirmed active patient recruitment in France, Italy and Spain for its Phase 2b programme. The surge came on volume of 127530.00 shares and left the share price at the session high. We view the move as a catalyst-driven rally tied to clinical progress rather than fundamental earnings improvement. The market closed with Aelis Farma SA among the best performers in the Healthcare/Biotechnology group in Europe.